Clinical Trials Logo

Influenza Infection clinical trials

View clinical trials related to Influenza Infection.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04933968 Terminated - Influenza Infection Clinical Trials

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Start date: March 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT) and solid organ transplant (SOT).

NCT ID: NCT01160237 Terminated - Influenza Infection Clinical Trials

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Start date: August 2010
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding study inclusion. Subjects never vaccinated with any H1N1 pandemic vaccine will be enrolled as control. This Protocol Posting has been updated following Amendment of the Protocol, July 2010. The impacted section is entry criteria.

NCT ID: NCT00647465 Terminated - Influenza Infection Clinical Trials

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer

GP-INFA
Start date: October 2005
Phase: Phase 3
Study type: Interventional

Influenza vaccination reduces the morbidity and mortality associated with influenza infection in at risk groups including the elderly and individuals with an impaired immune response, but is not totally protective in all recipient. Cytokines including type I interferons are known to play a key role in the innate immune response to virus infection and in the induction of the primary adaptive-immune response. Thus, we evaluated the safety of sublingual administration of IFNa and its effect on immune response to influenza vaccination in a randomized double-blind placebo controlled study in elderly institutionalized individuals.